Ruiz José, Villa María Dolores, Cutillas Natalia, López Gregorio, de Haro Concepción, Bautista Delia, Moreno Virtudes, Valencia Laura
Departamento de Química Inorgánica, Universidad de Murcia, E-30071-Murcia, Spain.
Inorg Chem. 2008 Jun 2;47(11):4490-505. doi: 10.1021/ic701873b. Epub 2008 Apr 30.
Palladium and platinum complexes with HmtpO (where HmtpO=4,7-dihydro-5-methyl-7-oxo[1,2,4]triazolo[1,5-a]pyrimidine, an analogue of the natural occurring nucleobase hypoxanthine) of the types [M(dmba)(PPh3)(HmtpO)]ClO4[dmba=N,C-chelating 2-(dimethylaminomethyl)phenyl; M=Pd or Pt], [Pd(N-N)(C6F5)(HmtpO)]ClO4[N-N=2,2'-bipyridine (bpy), 4,4'-dimethyl-2,2'-bipyridine (Me2bpy), or N, N, N', N'-tetramethylethylenediamine (tmeda)] and cis-[M(C6F5)2(HmtpO)2] (M=Pd or Pt) (head-to-head atropisomer in the solid state) have been obtained. Pd(II) and Pt(II) complexes with the anion of HmtpO of the types [Pd(tmeda)(C6F5)(mtpO)], [Pd(dmba)(micro-mtpO)] 2, and [NBu4]2[M(C6F5)2(micro-mtpO)]2(M=Pd or Pt) have been prepared starting from the corresponding hydroxometal complexes. Complexes containing simultaneously both the neutral HmtpO ligand and the anionic mtpO of the type [NBu4][M(C6F5)2(HmtpO)(mtpO)] (M=Pd or Pt) have been also obtained. In these mtpO-HmtpO metal complexes, for the first time, prototropic exchange is observed between the two heterocyclic ligands. The crystal structures of [Pd(dmba)(PPh 3)(HmtpO)]+, cis-[Pt(C6F5)2(HmtpO)2].acetone, [Pd(C6F5)(tmeda)(mtpO)].2H2O, [Pd(dmba)(micro-mtpO)]2, [NBu4]2[Pd(C6F5)2(micro-mtpO)]2.CH2Cl2.toluene, [NBu4]2Pt(C6F5)2(micro-mtpO).0.5(toluene), and [NBu4][Pt(C6F5)2(mtpO)(HmtpO)] have been established by X-ray diffraction. Values of IC50 were calculated for the new platinum complexes cis-[Pt(C6F5)2(HmtpO)2] and [Pt(dmba)(PPh3)(HmtpO)]ClO4 against a panel of human tumor cell lines representative of ovarian (A2780 and A2780 cisR), lung (NCI-H460), and breast cancers (T47D). At 48 h incubation time, both complexes were about 8-fold more active than cisplatin in T47D and show very low resistance factors against an A2780 cell line, which has acquired resistance to cisplatin. The DNA adduct formation of cis-[Pt(C6F5)2(HmtpO)2] and [Pt(dmba)(PPh3)(HmtpO)]ClO4 was followed by circular dichroism and electrophoretic mobility. Atomic force microscopy images of the modifications caused by these platinum complexes on plasmid DNA pB R322 were also obtained.
已制得钯和铂与HmtpO(其中HmtpO = 4,7 - 二氢 - 5 - 甲基 - 7 - 氧代[1,2,4]三唑并[1,5 - a]嘧啶,天然存在的核碱基次黄嘌呤的类似物)形成的配合物,其类型为[M(dmba)(PPh₃)(HmtpO)]ClO₄[dmba = N,C - 螯合的2 - (二甲基氨基甲基)苯基;M = Pd或Pt]、[Pd(N - N)(C₆F₅)(HmtpO)]ClO₄[N - N = 2,2'- 联吡啶(bpy)、4,4'- 二甲基 - 2,2'- 联吡啶(Me₂bpy)或N,N,N',N'- 四甲基乙二胺(tmeda)]以及顺式 - [M(C₆F₅)₂(HmtpO)₂](M = Pd或Pt)(固态下为头对头阻转异构体)。已从相应的羟基金属配合物出发,制备了类型为[Pd(tmeda)(C₆F₅)(mtpO)]、[Pd(dmba)(μ - mtpO)]₂和[NBu₄]₂[M(C₆F₅)₂(μ - mtpO)]₂(M = Pd或Pt)的钯(II)和铂(II)与HmtpO阴离子形成的配合物。还获得了同时含有中性HmtpO配体和阴离子mtpO的类型为[NBu₄][M(C₆F₅)₂(HmtpO)(mtpO)](M = Pd或Pt)的配合物。在这些mtpO - HmtpO金属配合物中,首次观察到两个杂环配体之间的质子转移交换。通过X射线衍射确定了[Pd(dmba)(PPh₃)(HmtpO)]⁺、顺式 - [Pt(C₆F₅)₂(HmtpO)₂]·丙酮、[Pd(C₆F₅)(tmeda)(mtpO)]·2H₂O、[Pd(dmba)(μ - mtpO)]₂、[NBu₄]₂[Pd(C₆F₅)₂(μ - mtpO)]₂·CH₂Cl₂·甲苯、[NBu₄]₂[Pt(C₆F₅)₂(μ - mtpO)]₂·0.5(甲苯)和[NBu₄][Pt(C₆F₅)₂(mtpO)(HmtpO)]的晶体结构。针对一组代表卵巢癌(A2780和A2780 cisR)、肺癌(NCI - H460)和乳腺癌(T₄₇D)的人类肿瘤细胞系,计算了新型铂配合物顺式 - [Pt(C₆F₅)₂(HmtpO)₂]和[Pt(dmba)(PPh₃)(HmtpO)]ClO₄的IC₅₀值。在48小时的孵育时间下,两种配合物在T₄₇D细胞系中的活性均比顺铂高约8倍,并且对已获得顺铂抗性的A2780细胞系显示出非常低的耐药因子。通过圆二色性和电泳迁移率跟踪了顺式 - [Pt(C₆F₅)₂(HmtpO)₂]和[Pt(dmba)(PPh₃)(HmtpO)]ClO₄的DNA加合物形成。还获得了这些铂配合物对质粒DNA pBR322造成修饰的原子力显微镜图像。